BRAF and cancer: The prevalence of high TMB, in the range associated with putative responses to immune checkpoint inhibitors, is also lower in metastatic BRAF mutated cancers, when evaluated from biopsy samples of metastatic sites compared with samples from biopsies of the primary tumor [20].